Ala. Admin. Code r. 540-X-26-.02

Current through Register Vol. 43, No. 1, October 31, 2024

Section 540-X-26-.02 - Collaborative Drug Therapy Management Agreement Required

(1) Physicians and pharmacists may only engage in Collaborative Drug Therapy Management when:

(a) An Agreement has been appropriately executed and a written attestation has been filed with and approved by the Board of Pharmacy and the Board of Medical Examiners; and

(b) The patient or the patient's authorized representative has signed an Agreement-specific consent that the patient is to receive services from a healthcare team, including a Collaborating Pharmacist.

(2) The patient's consent to treatment under a Collaborative Drug Therapy Management Agreement shall be made part of the patient record.

(3) The written attestation shall include the names of the Collaborating Pharmacist, Collaborating Physician, and any Covering Physician or Covering Pharmacist, if applicable, participating in the Agreement, the date of the Agreement, and a description of the scope of the services covered by the Agreement.

(4) The written attestation shall include a formulary and a list of services authorized by the Agreement.

(5) The Agreement and written attestation must be provided to the Board of Pharmacy and the Board of Medical Examiners no later than ten (10) days after the Agreement is signed by the parties.

(6) A copy of the Agreement, including any addendum, modification, or termination shall be accessible at each practice site and shall be made available to the Board of Pharmacy and Board of Medical Examiners for review upon request.

Ala. Admin. Code r. 540-X-26-.02

Adopted by Alabama Administrative Monthly Volume XXXIX, Issue No. 11, August 31, 2021, eff. 10/15/2021.

Author: Alabama Board of Medical Examiners

Statutory Authority:Code of Ala. 1975, § 34-24-53; Act 2019-368 (Code of Ala. 1975, § 34-23-77).